TNFRSF17 and Miyoshi myopathy: BCMA was recently reported to be uniformly expressed in most cases of MM by immunohistochemistry and flow cytometry 59, indicating that BCMA targeted CAR-T products may exert antimyeloma activity without serious adverse effects theoretically.